SYNARC to Present at ECCEO, in Valencia, Spain

San Francisco – March 15, 2011 - SYNARC, the world’s leading provider of medical imaging services for the pharmaceutical and biotechnology industries, announced today that several of the company’s scientific leaders will give key presentations at the European Congress on Osteoporosis & Osteoarthritis (ECCEO), in Valencia, Spain.  Among them are two oral presentations and one poster session:

BMD and BMC Improvements in Hip Total, Trabecular, and Cortical Bone Following Denosumab Treatment: QCT Results from the Freedom Trial (oral presentation). HK Genant, K Engelke, JR Zanchetta, A Høiseth, CK Yuen, S Stonkus, MA Bolognese, E Franek, T Fuerst, H Radcliffe, C Libanati.

Effects of the Cathepsin K Inhibitor, ONO-5334, on BMD as Measured by 3D QCT in the Hip and the Spine After 12 Months Treatment (oral presentation). K Engelke, S Nagase, T Fuerst, R Eastell, HK Genant, M Small, T Kuwayama, S Deacon.
Quantitative Morphometry on Spinal X-Rays: Initial Evaluation of a New Workflow Tool for Measuring Vertebral Body Height in Fractured Vertebrae (poster session). K Engelke, B Stampa, P Steiger, T Fuerst, HK Genant.
“Innovation and publication of new advances in imaging for clinical research are central to Synarc’s mission,” said Thomas Fuerst, Ph.D., Synarc’s Chief Science Officer and co-founder. “We are pleased to collaborate with our pharma and biotech partners on the presentation of results from two recently completed clinical trials, highlighting the value of QCT in both early and late phase clinical development.” Synarc also maintains a strong research program in vertebral fracture assessment, an important clinical hallmark of osteoporosis and staple of phase 3 clinical trials of new osteoporosis therapies.
With over 5,500 participants, the ECCEO has become the largest educational event and most vibrant clinical research forum for osteoporosis and osteoarthritis in Europe. The meeting will be attended by clinicians and researchers from around the world and offers a unique opportunity to hear about the latest developments in clinical practice, pharmaceutical research, and basic science relating to osteoporosis and osteoarthritis.

About Synarc

Synarc’s medical image analysis, biochemical marker, and clinical research center services enable life-science industry clients to execute clinical trials accurately while decreasing the time, uncertainty, and cost of product development. Synarc has partnered with industry leaders to bring numerous leading compounds to market across a broad spectrum of therapeutic areas. Our services integrate critical aspects of clinical-trial design and execution, from protocol design and subject recruitment to regulatory liaison on behalf of our clients.  Our expert radiologists and scientists are innovators in all aspects of medical image analysis and biochemical markers in drug development, and have pioneered many methods used in today’s clinical trials.

# # #
Media Contact:
Joy Valderrama
415 817-8919
joy.valderrama@synarc.com